Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis

Inclusion Criteria: * Males age 45-80 years * Diagnosis of prostate cancer * Status post IMRT and Palladium-103 seed implantation and initiated alpha blocker therapy with alfuzosin10mg daily or tamulosin 0.4mg bid at time of seed implantation * Baseline AUA score\< or =12 * May be on antiandrogenand/or alpha reductase therapy * Patients receiving IMRT followed by Palladium-103 Brachytherapy implantation as the primary therapy for prostate cancer with curatives intent - Exclusion Criteria: * History of insulin-dependent diabetes * Uncontrolled hypertention * History of symptomtic hypotension (including syncope and dizziness) * Pre-existing obstructive uropathy based on history of BPH and or Acute Urinary Retention * Pre-existing prostatitis either continuous or intermittent * Concurrent use of any other anticholinergics * previous or concurrent usage of LHRH agonist